There’s itch relief.
Then there’s Zenrelia.
Zenrelia is the NEW treatment for canine allergic itch and inflammation that provides fast and effective relief with just once-daily dosing from the very start1.
Zenrelia is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
Zenrelia targets itch where it starts
Zenrelia is a Janus Kinase (JAK) inhibitor designed to disrupt cytokine signaling pathways that trigger itch and inflammation related to canine allergic and atopic dermatitis2.
Gets dogs back to normal
Works fast
Visible improvements in allergic itch from day one²
Optimized dosing
• No loading or tapering, just once a day from the start
• Minimizes opportunity for rebound of itch¹
Continuous efficacy
• Continues to relieve itch and inflammation over the long term¹
• Reduces lesions and inflammation, improving skin condition²
• In a Head to Head clinical trial, 77% of Zenrelia-treated dogs achieved clinical remission from pruritus compared to 53% of Apoquel-treated dogs¹*
Normal itch level/clinical remission is defined as a state in which the disease severity is minimal and does not significantly impact a patient's daily life, with an itch score of “normal” (PVAS <2).
Safety
In clinical trials, the most observed adverse events were vomiting, diarrhea and lethargy.
Tales of Zen
Discover real-life examples of dogs who have benefitted from Zenrelia
Zenrelia is simple to use
Convenience
Consistent, once-daily dosing – given from the comfort of home, with or without food.
Compliance
Routine, once-daily dosing can support owner adherence.2
Cost Effective
Owners pay for just one dose a day, regardless of duration or how often you initiate therapy**.
Sources of Zen
INDICATIONS
Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
IMPORTANT SAFETY INFORMATION
Read the entire package insert before using this drug, including the Boxed Warning.
For Full prescribing information call 1 888 545 5973 or visit http://www.elancolabels.com/us/zenrelia
WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.
